Vitamin B6 may tame mood swings from brain tumor seizure drug
NCT ID NCT07271966
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking a daily vitamin B6 supplement can reduce anger and mood changes caused by the seizure drug levetiracetam in people with brain tumors. Fifty adults with brain tumor-related epilepsy who have been on levetiracetam for 6 weeks to 6 months will take 100 mg of vitamin B6 daily for 8 to 12 weeks. Patients and their caregivers will report mood changes through questionnaires to see if the vitamin helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vitamin B6 (pyridoxine) 100 mg daily supplement
What this could lead to
If it works, this could offer a simple, low-cost way to reduce anger and mood problems caused by levetiracetam in brain tumor patients.
What could go wrong
This is a small, early-stage study with only 50 participants and no placebo group, so results may not be conclusive. Vitamin B6 is generally safe, but high doses can cause nerve damage in some people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••